Teva Pharmaceutical Industries Limited Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | $0.51 | $0.51 | $0.51 |
| Q2 2024 | 3 | $0.55 | $0.55 | $0.55 |
| Q3 2024 | 5 | $0.61 | $0.69 | $0.66 |
| Q4 2024 | 3 | $0.72 | $0.72 | $0.72 |
| Q1 2025 | 4 | $0.53 | $0.53 | $0.53 |
| Q2 2025 | 4 | $0.67 | $0.67 | $0.67 |
| Q3 2025 | 4 | $0.72 | $0.72 | $0.72 |
| Q4 2025 | 4 | $0.80 | $0.80 | $0.80 |
Teva Pharmaceutical Industries Limited Earnings Date And Information
Teva Pharmaceutical Industries Limited last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.3857 earnings per share for the quarter, missing analysts' consensus estimates of $0.66 by $1.0457. The company had revenue of 4.33 B for the quarter and had revenue of 15.85 B for the year. Teva Pharmaceutical Industries Limited has generated $-1 earnings per share over the last year ($-0.5 diluted earnings per share) and currently has a price-to-earnings ratio of -19.99. Teva Pharmaceutical Industries Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Teva Pharmaceutical Industries Limited Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | $0.66 | -$0.39 | -1.05 | $4.14 B | $4.33 B |
| 07/31/2024 | Q2 2024 | $0.57 | -$0.75 | -1.32 | $4.06 B | $4.16 B |
| 05/08/2024 | Q1 2024 | $0.51 | -$0.12 | -0.63 | $3.83 B | |
| 02/12/2024 | Q4 2023 | $0.41 | $4.46 B | |||
| 11/09/2023 | Q3 2023 | $0.07 | $3.73 B | $3.85 B | ||
| 08/02/2023 | Q2 2023 | $0.54 | -$0.77 | -1.31 | $3.71 B | $3.88 B |
| 05/10/2023 | Q1 2023 | $0.57 | -$0.18 | -0.75 | $3.66 B | |
| 02/10/2023 | Q4 2022 | -$1.10 | $3.88 B | |||
| 11/03/2022 | Q3 2022 | $0.61 | $0.05 | -0.56 | $3.84 B | $3.60 B |
| 07/27/2022 | Q2 2022 | -$0.21 | $3.78 B | $3.79 B | ||
| 05/03/2022 | Q1 2022 | $0.55 | -$0.86 | -1.41 | $3.66 B | |
| 02/09/2022 | Q4 2021 | $0.74 | -$0.14 | -0.88 | $4.10 B | |
| 10/27/2021 | Q3 2021 | $0.65 | $0.26 | -0.39 | $4.03 B | $3.89 B |
| 07/28/2021 | Q2 2021 | $0.57 | $0.19 | -0.38 | $4.02 B | $3.91 B |
| 04/28/2021 | Q1 2021 | $0.58 | $0.07 | -0.51 | $3.98 B | |
| 02/10/2021 | Q4 2020 | $0.62 | $0.14 | -0.48 | $4.45 B | |
| 11/05/2020 | Q3 2020 | $0.58 | -$3.97 | -4.55 | $4.07 B | $3.98 B |
| 08/05/2020 | Q2 2020 | $0.51 | $0.13 | -0.38 | $3.93 B | $3.87 B |
| 05/07/2020 | Q1 2020 | $0.59 | $0.06 | -0.53 | $4.36 B | |
| 02/21/2020 | Q4 2019 | $0.10 | $4.47 B |
Teva Pharmaceutical Industries Limited Earnings: Frequently Asked Questions
-
When is Teva Pharmaceutical Industries Limited's earnings date?
Teva Pharmaceutical Industries Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
How can I listen to Teva Pharmaceutical Industries Limited's earnings conference call?
The conference call for Teva Pharmaceutical Industries Limited's latest earnings report can be listened to online.
-
How can I read Teva Pharmaceutical Industries Limited's conference call transcript?
The conference call transcript for Teva Pharmaceutical Industries Limited's latest earnings report can be read online.
-
How much revenue does Teva Pharmaceutical Industries Limited generate each year?
Teva Pharmaceutical Industries Limited (:TEVA) has a recorded annual revenue of $15.85 B.
-
How much profit does Teva Pharmaceutical Industries Limited generate each year?
Teva Pharmaceutical Industries Limited (:TEVA) has a recorded net income of $15.85 B. Teva Pharmaceutical Industries Limited has generated $-0.5 earnings per share over the last four quarters.
-
What is Teva Pharmaceutical Industries Limited's price-to-earnings ratio?
Teva Pharmaceutical Industries Limited (:TEVA) has a price-to-earnings ratio of -19.99 and price/earnings-to-growth ratio is -4.1.
